01:00 PM EDT, 07/08/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month target price to $367 from $343 based on our net present value (NPV) analysis. We lift our 2025 EPS estimate to $1.15 from $0.69, as we see improved profitability for the remainder of the year. We increase our 2026 EPS estimate to $4.62 from $3.95. Following the approval of Amvuttra (vutrisiran) for the treatment of ATTR amyloidosis with cardiomyopathy by the European Commission, broadening the therapy's indication, we saw a rally in ALNY shares in the last month, up 7.7% M/M. These results were based on satisfactory results from the key HELIOS-B Phase 3 study in which the therapy met all pre-specified primary and secondary endpoints across the overall and monotherapy populations. According to the company, the therapy has a solid addressable market, with around 100K people suffering from ATTR amyloidosis across Europe and most with cardiomyopathy.